



The Stowers Story

For investors who believe
in making a difference



For investors who want to make a difference in the world, Zurich Investments Global Growth strategies combine investment growth opportunities with positive impact.

1.7 Billion
directed into
finding a cure for
gene-based
diseases since
2000



Invest to make a difference

From finding a cure for cancer to discovering the genetic triggers for Alzheimer's, these big challenges demand a new approach to long-term, sustainable research funding. Since 2000, American Century Investments has already provided more than \$1.7 billion* through dividends to biomedical research into gene-based diseases – while consistently providing growth opportunities for investors.

American Century Investments (ACI) has a very different ownership structure, with the Stowers Institute for Medical Research holding more than 40% equity. This means, every year, more than 40% of ACI's company profits are paid as dividends to provide sustainable funding to the Institute – allowing scientists to focus on their research.

This means, through our strategic partnership with American Century Investments, investors can help fund important medical research breakthroughs for life-threatening diseases, including cancer, diabetes and dementia.

Long-term, sustainable investment returns are also part of American Century's DNA, providing investors with capital growth opportunities while also saving lives. Looking for accelerating and sustainable growth, they identify global stocks with the potential to outperform.

For investors who like to think differently about investment returns, it's an opportunity to make a positive impact.

Performance impact

Operating for more than 60 years, American Century's investment approach actively looks for inflection points in business fundamentals; that moment where earnings growth accelerates. The aim is sustainable out-performance – and stronger returns.

With three options for investing in this strategy, investors have the choice to suit their portfolio needs.

American Century Investments has

USD \$213 billion



in assets under management as at 31 Dec 2020

Positive Impact

ACI's ownership model is dedicated to making a difference in the world.

40%



Jim and Virginia Stowers endowed more than 40% equity in ACI to Stowers Institute for Medical Research to ensure viable, long-term funding revenue.

The Institute's breakthrough treatments include c.novyi-NT, which can eat away at tumours without destroying healthy tissue, and BVD-523, which targets a genetic vulnerability.



*As at 31 December 2020.



Generations of impact

- Cancer is the leading cause of death in Australia, with one in two Australians diagnosed by the time they reach 85¹
- Almost half a million Australians live with dementia, and it is the second leading cause of death²
- Around 1.7million Australians have diabetes, and it is Australia's fastest-growing chronic condition³

The Institute's biomedical research seeks to understand the genetic mechanisms underlying life-threatening diseases like these.

This gives investors the opportunity to change millions of lives – including those they care about most.

1 <https://www.cancer.org.au/about-cancer/what-is-cancer/facts-and-figures.html>

2 <https://www.dementia.org.au/statistics> September 2018

3 <https://www.diabetesaustralia.com.au/about-diabetes>

150 million

Globally, the Stowers Institute for Medical Research believes the potential impact of research results will give hope to more than 150 million patients in future generations.



To learn more about the Stowers story, and how you can invest in the Zurich Investments Global Growth strategy:

Visit www.zurich.com.au/stowers-investor

Contact us on 131 551 or at client.service@zurich.com.au

Zurich Australia Limited
ABN 92 000 010 195, AFSLN 232510
118 Mount St, North Sydney NSW 2060
www.zurich.com.au

Important Information: This publication is dated October 2021, is given in good faith and is derived from sources believed to be accurate as at this date, which may be subject to change. It should not be considered to be a comprehensive statement on any matter and should not be relied on as such. It does not take into account the personal objectives, financial situation or needs of any person. You should consider these factors, the appropriateness of the information, and the particular fund's Product Disclosure Statement (available from your adviser or at zurich.com.au) before making any decisions. Furthermore, this product has been designed to meet certain objectives, financial situations and needs, which are described in our Target Market Determination available at zurich.com.au/tmd. Past performance is not a reliable indicator of future performance. The funds are issued by Zurich Investment Management Limited ABN 56 063 278 400 AFSL 232511. GINN: FVHHKJ00012.ME.036.

DFOY-016907-2021

